 | • レポートコード：MRC2012A3017 • 出版社/出版日：GlobalInfoResearch / 2020年12月21日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、107ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医薬品、医療 |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、代謝障害治療薬の世界市場を広く調査・分析し、今後の市場展望をまとめております。代謝障害治療薬の種類別市場規模（グリコーゲン代謝疾患治療薬、脂質代謝疾患治療薬、アミノ酸代謝治療薬、その他）、用途別市場規模（病院、小売薬局）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、メーカー別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・市場概要 ・メーカー情報（販売量、市場シェア、製品概要、SWOT分析）：Merck、Fuji yakuhin、Astra Zeneca、Novartis、Kythera、Takeda Pharmaceutical、Metsubishi Tanabe Pharma、KOWA、Boehringer Ingelheim、LG Life Science、 ・地域別グローバル市場分析 2015年-2020年 ・代謝障害治療薬の北米市場（アメリカ、カナダ、メキシコ） ・代謝障害治療薬のヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・代謝障害治療薬のアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・代謝障害治療薬の南米市場（ブラジル、アルゼンチン） ・代謝障害治療薬の中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：グリコーゲン代謝疾患治療薬、脂質代謝疾患治療薬、アミノ酸代謝治療薬、その他 ・用途別分析：病院、小売薬局 ・地域別市場規模予測 2021年-2025年 ・販売チャネル、流通業者、代理店 ・調査の結果・結論 |
Market Overview
The global Drugs for Metabolic Disorders market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.
The Drugs for Metabolic Disorders market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
Market segmentation
Drugs for Metabolic Disorders market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, Drugs for Metabolic Disorders market has been segmented into
Glycogen Metabolism Disease Drug
Lipid Metabolism Disease Drug
Amino Acid Metabolism Drug
Other
By Application, Drugs for Metabolic Disorders has been segmented into:
Hospital
Retail Pharmacy
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Drugs for Metabolic Disorders market presented in the report. This section sheds light on the sales growth of different regional and country-level Drugs for Metabolic Disorders markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Drugs for Metabolic Disorders market.
The report offers in-depth assessment of the growth and other aspects of the Drugs for Metabolic Disorders market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, etc.)
Middle East & Africa (Saudi Arabia, Egypt, Nigeria and South Africa)
Competitive Landscape and Drugs for Metabolic Disorders Market Share Analysis
Drugs for Metabolic Disorders competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Drugs for Metabolic Disorders sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Drugs for Metabolic Disorders sales, revenue and market share for each player covered in this report.
The major players covered in Drugs for Metabolic Disorders are:
Merck
Fuji yakuhin
Astra Zeneca
Novartis
Kythera
Takeda Pharmaceutical
Metsubishi Tanabe Pharma
KOWA
Boehringer Ingelheim
LG Life Science
Among other players domestic and global, Drugs for Metabolic Disorders market share data is available for global, North America, Europe, Asia-Pacific, Middle East and Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Drugs for Metabolic Disorders product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Drugs for Metabolic Disorders, with price, sales, revenue and global market share of Drugs for Metabolic Disorders in 2018 and 2019.
Chapter 3, the Drugs for Metabolic Disorders competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Drugs for Metabolic Disorders breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2015 to 2020.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2015 to 2020.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2015 to 2020.
Chapter 12, Drugs for Metabolic Disorders market forecast, by regions, type and application, with sales and revenue, from 2020 to 2025.
Chapter 13, 14 and 15, to describe Drugs for Metabolic Disorders sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Table of Contents
1 Market Overview
1.1 Drugs for Metabolic Disorders Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Drugs for Metabolic Disorders Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Glycogen Metabolism Disease Drug
1.2.3 Lipid Metabolism Disease Drug
1.2.4 Amino Acid Metabolism Drug
1.2.5 Other
1.3 Market Analysis by Application
1.3.1 Overview: Global Drugs for Metabolic Disorders Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.4 Overview of Global Drugs for Metabolic Disorders Market
1.4.1 Global Drugs for Metabolic Disorders Market Status and Outlook (2015-2025)
1.4.2 North America (United States, Canada and Mexico)
1.4.3 Europe (Germany, France, United Kingdom, Russia and Italy)
1.4.4 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.5 South America, Middle East & Africa
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Merck
2.1.1 Merck Details
2.1.2 Merck Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Merck SWOT Analysis
2.1.4 Merck Product and Services
2.1.5 Merck Drugs for Metabolic Disorders Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.2 Fuji yakuhin
2.2.1 Fuji yakuhin Details
2.2.2 Fuji yakuhin Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Fuji yakuhin SWOT Analysis
2.2.4 Fuji yakuhin Product and Services
2.2.5 Fuji yakuhin Drugs for Metabolic Disorders Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.3 Astra Zeneca
2.3.1 Astra Zeneca Details
2.3.2 Astra Zeneca Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Astra Zeneca SWOT Analysis
2.3.4 Astra Zeneca Product and Services
2.3.5 Astra Zeneca Drugs for Metabolic Disorders Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.4 Novartis
2.4.1 Novartis Details
2.4.2 Novartis Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Novartis SWOT Analysis
2.4.4 Novartis Product and Services
2.4.5 Novartis Drugs for Metabolic Disorders Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.5 Kythera
2.5.1 Kythera Details
2.5.2 Kythera Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Kythera SWOT Analysis
2.5.4 Kythera Product and Services
2.5.5 Kythera Drugs for Metabolic Disorders Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.6 Takeda Pharmaceutical
2.6.1 Takeda Pharmaceutical Details
2.6.2 Takeda Pharmaceutical Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Takeda Pharmaceutical SWOT Analysis
2.6.4 Takeda Pharmaceutical Product and Services
2.6.5 Takeda Pharmaceutical Drugs for Metabolic Disorders Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.7 Metsubishi Tanabe Pharma
2.7.1 Metsubishi Tanabe Pharma Details
2.7.2 Metsubishi Tanabe Pharma Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Metsubishi Tanabe Pharma SWOT Analysis
2.7.4 Metsubishi Tanabe Pharma Product and Services
2.7.5 Metsubishi Tanabe Pharma Drugs for Metabolic Disorders Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.8 KOWA
2.8.1 KOWA Details
2.8.2 KOWA Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 KOWA SWOT Analysis
2.8.4 KOWA Product and Services
2.8.5 KOWA Drugs for Metabolic Disorders Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.9 Boehringer Ingelheim
2.9.1 Boehringer Ingelheim Details
2.9.2 Boehringer Ingelheim Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 Boehringer Ingelheim SWOT Analysis
2.9.4 Boehringer Ingelheim Product and Services
2.9.5 Boehringer Ingelheim Drugs for Metabolic Disorders Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.10 LG Life Science
2.10.1 LG Life Science Details
2.10.2 LG Life Science Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 LG Life Science SWOT Analysis
2.10.4 LG Life Science Product and Services
2.10.5 LG Life Science Drugs for Metabolic Disorders Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
3 Sales, Revenue and Market Share by Manufacturer
3.1 Global Drugs for Metabolic Disorders Sales and Market Share by Manufacturer (2018-2019)
3.2 Global Drugs for Metabolic Disorders Revenue and Market Share by Manufacturer (2018-2019)
3.3 Market Concentration Rate
3.3.1 Top 3 Drugs for Metabolic Disorders Manufacturer Market Share in 2019
3.3.2 Top 6 Drugs for Metabolic Disorders Manufacturer Market Share in 2019
3.4 Market Competition Trend
4 Global Market Analysis by Regions
4.1 Global Drugs for Metabolic Disorders Sales, Revenue and Market Share by Regions
4.1.1 Global Drugs for Metabolic Disorders Sales and Market Share by Regions (2015-2020)
4.1.2 Global Drugs for Metabolic Disorders Revenue and Market Share by Regions (2015-2020)
4.2 North America Drugs for Metabolic Disorders Sales and Growth Rate (2015-2020)
4.3 Europe Drugs for Metabolic Disorders Sales and Growth Rate (2015-2020)
4.4 Asia-Pacific Drugs for Metabolic Disorders Sales and Growth Rate (2015-2020)
4.5 South America Drugs for Metabolic Disorders Sales and Growth Rate (2015-2020)
4.6 Middle East and Africa Drugs for Metabolic Disorders Sales and Growth Rate (2015-2020)
5 North America by Country
5.1 North America Drugs for Metabolic Disorders Sales, Revenue and Market Share by Country
5.1.1 North America Drugs for Metabolic Disorders Sales and Market Share by Country (2015-2020)
5.1.2 North America Drugs for Metabolic Disorders Revenue and Market Share by Country (2015-2020)
5.2 United States Drugs for Metabolic Disorders Sales and Growth Rate (2015-2020)
5.3 Canada Drugs for Metabolic Disorders Sales and Growth Rate (2015-2020)
5.4 Mexico Drugs for Metabolic Disorders Sales and Growth Rate (2015-2020)
6 Europe by Country
6.1 Europe Drugs for Metabolic Disorders Sales, Revenue and Market Share by Country
6.1.1 Europe Drugs for Metabolic Disorders Sales and Market Share by Country (2015-2020)
6.1.2 Europe Drugs for Metabolic Disorders Revenue and Market Share by Country (2015-2020)
6.2 Germany Drugs for Metabolic Disorders Sales and Growth Rate (2015-2020)
6.3 UK Drugs for Metabolic Disorders Sales and Growth Rate (2015-2020)
6.4 France Drugs for Metabolic Disorders Sales and Growth Rate (2015-2020)
6.5 Russia Drugs for Metabolic Disorders Sales and Growth Rate (2015-2020)
6.6 Italy Drugs for Metabolic Disorders Sales and Growth Rate (2015-2020)
7 Asia-Pacific by Regions
7.1 Asia-Pacific Drugs for Metabolic Disorders Sales, Revenue and Market Share by Regions
7.1.1 Asia-Pacific Drugs for Metabolic Disorders Sales and Market Share by Regions (2015-2020)
7.1.2 Asia-Pacific Drugs for Metabolic Disorders Revenue and Market Share by Regions (2015-2020)
7.2 China Drugs for Metabolic Disorders Sales and Growth Rate (2015-2020)
7.3 Japan Drugs for Metabolic Disorders Sales and Growth Rate (2015-2020)
7.4 Korea Drugs for Metabolic Disorders Sales and Growth Rate (2015-2020)
7.5 India Drugs for Metabolic Disorders Sales and Growth Rate (2015-2020)
7.6 Southeast Asia Drugs for Metabolic Disorders Sales and Growth Rate (2015-2020)
7.7 Australia Drugs for Metabolic Disorders Sales and Growth Rate (2015-2020)
8 South America by Country
8.1 South America Drugs for Metabolic Disorders Sales, Revenue and Market Share by Country
8.1.1 South America Drugs for Metabolic Disorders Sales and Market Share by Country (2015-2020)
8.1.2 South America Drugs for Metabolic Disorders Revenue and Market Share by Country (2015-2020)
8.2 Brazil Drugs for Metabolic Disorders Sales and Growth Rate (2015-2020)
8.3 Argentina Drugs for Metabolic Disorders Sales and Growth Rate (2015-2020)
9 Middle East & Africa by Countries
9.1 Middle East & Africa Drugs for Metabolic Disorders Sales, Revenue and Market Share by Country
9.1.1 Middle East & Africa Drugs for Metabolic Disorders Sales and Market Share by Country (2015-2020)
9.1.2 Middle East & Africa Drugs for Metabolic Disorders Revenue and Market Share by Country (2015-2020)
9.2 Saudi Arabia Drugs for Metabolic Disorders Sales and Growth Rate (2015-2020)
9.3 Turkey Drugs for Metabolic Disorders Sales and Growth Rate (2015-2020)
9.4 Egypt Drugs for Metabolic Disorders Sales and Growth Rate (2015-2020)
9.5 South Africa Drugs for Metabolic Disorders Sales and Growth Rate (2015-2020)
10 Market Segment by Type
10.1 Global Drugs for Metabolic Disorders Sales and Market Share by Type (2015-2020)
10.2 Global Drugs for Metabolic Disorders Revenue and Market Share by Type (2015-2020)
10.3 Global Drugs for Metabolic Disorders Price by Type (2015-2020)
11 Global Drugs for Metabolic Disorders Market Segment by Application
11.1 Global Drugs for Metabolic Disorders Sales Market Share by Application (2015-2020)
11.2 Global Drugs for Metabolic Disorders Revenue Market Share by Application (2015-2020)
11.3 Global Drugs for Metabolic Disorders Price by Application (2015-2020)
12 Market Forecast
12.1 Global Drugs for Metabolic Disorders Sales, Revenue and Growth Rate (2021-2025)
12.2 Drugs for Metabolic Disorders Market Forecast by Regions (2021-2025)
12.2.1 North America Drugs for Metabolic Disorders Market Forecast (2021-2025)
12.2.2 Europe Drugs for Metabolic Disorders Market Forecast (2021-2025)
12.2.3 Asia-Pacific Drugs for Metabolic Disorders Market Forecast (2021-2025)
12.2.4 South America Drugs for Metabolic Disorders Market Forecast (2021-2025)
12.2.5 Middle East & Africa Drugs for Metabolic Disorders Market Forecast (2021-2025)
12.3 Drugs for Metabolic Disorders Market Forecast by Type (2021-2025)
12.3.1 Global Drugs for Metabolic Disorders Sales Forecast by Type (2021-2025)
12.3.2 Global Drugs for Metabolic Disorders Market Share Forecast by Type (2021-2025)
12.4 Drugs for Metabolic Disorders Market Forecast by Application (2021-2025)
12.4.1 Global Drugs for Metabolic Disorders Sales Forecast by Application (2021-2025)
12.4.2 Global Drugs for Metabolic Disorders Market Share Forecast by Application (2021-2025)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
15.3 Disclaimer
15.4 About US
Table 1. Global Drugs for Metabolic Disorders Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Drugs for Metabolic Disorders by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Drugs for Metabolic Disorders Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Market Opportunities in Next Few Years
Table 5. Market Risks Analysis
Table 6. Market Drivers
Table 7. Merck Basic Information, Manufacturing Base and Competitors
Table 8. Merck Drugs for Metabolic Disorders Major Business
Table 9. Merck Drugs for Metabolic Disorders Total Revenue (USD Million) (2017-2018)
Table 10. Merck SWOT Analysis
Table 11. Merck Drugs for Metabolic Disorders Product and Services
Table 12. Merck Drugs for Metabolic Disorders Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 13. Fuji yakuhin Basic Information, Manufacturing Base and Competitors
Table 14. Fuji yakuhin Drugs for Metabolic Disorders Major Business
Table 15. Fuji yakuhin Drugs for Metabolic Disorders Total Revenue (USD Million) (2017-2018)
Table 16. Fuji yakuhin SWOT Analysis
Table 17. Fuji yakuhin Drugs for Metabolic Disorders Product and Services
Table 18. Fuji yakuhin Drugs for Metabolic Disorders Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 19. Astra Zeneca Basic Information, Manufacturing Base and Competitors
Table 20. Astra Zeneca Drugs for Metabolic Disorders Major Business
Table 21. Astra Zeneca Drugs for Metabolic Disorders Total Revenue (USD Million) (2017-2018)
Table 22. Astra Zeneca SWOT Analysis
Table 23. Astra Zeneca Drugs for Metabolic Disorders Product and Services
Table 24. Astra Zeneca Drugs for Metabolic Disorders Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 25. Novartis Basic Information, Manufacturing Base and Competitors
Table 26. Novartis Drugs for Metabolic Disorders Major Business
Table 27. Novartis Drugs for Metabolic Disorders Total Revenue (USD Million) (2017-2018)
Table 28. Novartis SWOT Analysis
Table 29. Novartis Drugs for Metabolic Disorders Product and Services
Table 30. Novartis Drugs for Metabolic Disorders Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 31. Kythera Basic Information, Manufacturing Base and Competitors
Table 32. Kythera Drugs for Metabolic Disorders Major Business
Table 33. Kythera Drugs for Metabolic Disorders Total Revenue (USD Million) (2017-2018)
Table 34. Kythera SWOT Analysis
Table 35. Kythera Drugs for Metabolic Disorders Product and Services
Table 36. Kythera Drugs for Metabolic Disorders Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 37. Takeda Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 38. Takeda Pharmaceutical Drugs for Metabolic Disorders Major Business
Table 39. Takeda Pharmaceutical Drugs for Metabolic Disorders Total Revenue (USD Million) (2017-2018)
Table 40. Takeda Pharmaceutical SWOT Analysis
Table 41. Takeda Pharmaceutical Drugs for Metabolic Disorders Product and Services
Table 42. Takeda Pharmaceutical Drugs for Metabolic Disorders Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 43. Metsubishi Tanabe Pharma Basic Information, Manufacturing Base and Competitors
Table 44. Metsubishi Tanabe Pharma Drugs for Metabolic Disorders Major Business
Table 45. Metsubishi Tanabe Pharma Drugs for Metabolic Disorders Total Revenue (USD Million) (2017-2018)
Table 46. Metsubishi Tanabe Pharma SWOT Analysis
Table 47. Metsubishi Tanabe Pharma Drugs for Metabolic Disorders Product and Services
Table 48. Metsubishi Tanabe Pharma Drugs for Metabolic Disorders Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 49. KOWA Basic Information, Manufacturing Base and Competitors
Table 50. KOWA Drugs for Metabolic Disorders Major Business
Table 51. KOWA Drugs for Metabolic Disorders Total Revenue (USD Million) (2017-2018)
Table 52. KOWA SWOT Analysis
Table 53. KOWA Drugs for Metabolic Disorders Product and Services
Table 54. KOWA Drugs for Metabolic Disorders Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 55. Boehringer Ingelheim Basic Information, Manufacturing Base and Competitors
Table 56. Boehringer Ingelheim Drugs for Metabolic Disorders Major Business
Table 57. Boehringer Ingelheim Drugs for Metabolic Disorders Total Revenue (USD Million) (2017-2018)
Table 58. Boehringer Ingelheim SWOT Analysis
Table 59. Boehringer Ingelheim Drugs for Metabolic Disorders Product and Services
Table 60. Boehringer Ingelheim Drugs for Metabolic Disorders Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 61. LG Life Science Basic Information, Manufacturing Base and Competitors
Table 62. LG Life Science Drugs for Metabolic Disorders Major Business
Table 63. LG Life Science Drugs for Metabolic Disorders Total Revenue (USD Million) (2017-2018)
Table 64. LG Life Science SWOT Analysis
Table 65. LG Life Science Drugs for Metabolic Disorders Product and Services
Table 66. LG Life Science Drugs for Metabolic Disorders Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 67. Global Drugs for Metabolic Disorders Sales by Manufacturer (2018-2019) (K Units)
Table 68. Global Drugs for Metabolic Disorders Revenue by Manufacturer (2018-2019) (USD Million)
Table 69. Global Drugs for Metabolic Disorders Sales by Regions (2015-2020) (K Units)
Table 70. Global Drugs for Metabolic Disorders Sales Market Share by Regions (2015-2020)
Table 71. Global Drugs for Metabolic Disorders Revenue by Regions (2015-2020) (USD Million)
Table 72. North America Drugs for Metabolic Disorders Sales by Countries (2015-2020) (K Units)
Table 73. North America Drugs for Metabolic Disorders Sales Market Share by Countries (2015-2020)
Table 74. North America Drugs for Metabolic Disorders Revenue by Countries (2015-2020) (USD Million)
Table 75. North America Drugs for Metabolic Disorders Revenue Market Share by Countries (2015-2020)
Table 76. Europe Drugs for Metabolic Disorders Sales by Countries (2015-2020) (K Units)
Table 77. Europe Drugs for Metabolic Disorders Sales Market Share by Countries (2015-2020)
Table 78. Europe Drugs for Metabolic Disorders Revenue by Countries (2015-2020) (USD Million)
Table 79. Asia-Pacific Drugs for Metabolic Disorders Sales by Regions (2015-2020) (K Units)
Table 80. Asia-Pacific Drugs for Metabolic Disorders Sales Market Share by Regions (2015-2020)
Table 81. Asia-Pacific Drugs for Metabolic Disorders Revenue by Regions (2015-2020) (USD Million)
Table 82. South America Drugs for Metabolic Disorders Sales by Countries (2015-2020) (K Units)
Table 83. South America Drugs for Metabolic Disorders Sales Market Share by Countries (2015-2020)
Table 84. South America Drugs for Metabolic Disorders Revenue by Countries (2015-2020) (USD Million)
Table 85. South America Drugs for Metabolic Disorders Revenue Market Share by Countries (2015-2020)
Table 86. Middle East & Africa Drugs for Metabolic Disorders Sales by Countries (2015-2020) (K Units)
Table 87. Middle East & Africa Drugs for Metabolic Disorders Sales Market Share by Countries (2015-2020)
Table 88. Middle East & Africa Drugs for Metabolic Disorders Revenue by Countries (2015-2020) (USD Million)
Table 89. Middle East & Africa Drugs for Metabolic Disorders Revenue Market Share by Countries (2015-2020)
Table 90. Global Drugs for Metabolic Disorders Sales by Type (2015-2020) (K Units)
Table 91. Global Drugs for Metabolic Disorders Sales Share by Type (2015-2020)
Table 92. Global Drugs for Metabolic Disorders Revenue by Type (2015-2020) (USD Million)
Table 93. Global Drugs for Metabolic Disorders Revenue Share by Type (2015-2020)
Table 94. Global Drugs for Metabolic Disorders Sales by Application (2015-2020) (K Units)
Table 95. Global Drugs for Metabolic Disorders Sales Share by Application (2015-2020)
Table 96. Global Drugs for Metabolic Disorders Sales Forecast by Regions (2021-2025) (K Units)
Table 97. Global Drugs for Metabolic Disorders Market Share Forecast by Regions (2021-2025)
Table 98. Global Drugs for Metabolic Disorders Sales Forecast by Type (2021-2025) (K Units)
Table 99. Global Drugs for Metabolic Disorders Market Share Forecast by Type (2021-2025)
Table 100. Global Drugs for Metabolic Disorders Sales Forecast by Application (2021-2025)
Table 101. Global Drugs for Metabolic Disorders Market Share Forecast by Application (2021-2025)
Table 102. Direct Channel Pros & Cons
Table 103. Indirect Channel Pros & Cons
Table 104. Distributors/Traders/ Dealers List
List of Figures
Figure 1. Drugs for Metabolic Disorders Picture
Figure 2. Global Sales Market Share of Drugs for Metabolic Disorders by Type in 2019
Figure 3. Glycogen Metabolism Disease Drug Picture
Figure 4. Lipid Metabolism Disease Drug Picture
Figure 5. Amino Acid Metabolism Drug Picture
Figure 6. Other Picture
Figure 7. Drugs for Metabolic Disorders Sales Market Share by Application in 2018
Figure 8. Hospital Picture
Figure 9. Retail Pharmacy Picture
Figure 10. Global Drugs for Metabolic Disorders Market Status and Outlook (2015-2025) (USD Million)
Figure 11. United States Drugs for Metabolic Disorders Revenue (Value) and Growth Rate (2015-2025)
Figure 12. Canada Drugs for Metabolic Disorders Revenue (Value) and Growth Rate (2015-2025)
Figure 13. Mexico Drugs for Metabolic Disorders Revenue (Value) and Growth Rate (2015-2025)
Figure 14. Germany Drugs for Metabolic Disorders Revenue (Value) and Growth Rate (2015-2025)
Figure 15. France Drugs for Metabolic Disorders Revenue (Value) and Growth Rate (2015-2025)
Figure 16. UK Drugs for Metabolic Disorders Revenue (Value) and Growth Rate (2015-2025)
Figure 17. Russia Drugs for Metabolic Disorders Revenue (Value) and Growth Rate (2015-2025)
Figure 18. Italy Drugs for Metabolic Disorders Revenue (Value) and Growth Rate (2015-2025)
Figure 19. China Drugs for Metabolic Disorders Revenue (Value) and Growth Rate (2015-2025)
Figure 20. Japan Drugs for Metabolic Disorders Revenue (Value) and Growth Rate (2015-2025)
Figure 21. Korea Drugs for Metabolic Disorders Revenue (Value) and Growth Rate (2015-2025)
Figure 22. India Drugs for Metabolic Disorders Revenue (Value) and Growth Rate (2015-2025)
Figure 23. Southeast Asia Drugs for Metabolic Disorders Revenue (Value) and Growth Rate (2015-2025)
Figure 24. Australia Drugs for Metabolic Disorders Revenue (Value) and Growth Rate (2015-2025) (USD Million)
Figure 25. Brazil Drugs for Metabolic Disorders Revenue (Value) and Growth Rate (2015-2025)
Figure 26. Egypt Drugs for Metabolic Disorders Revenue (Value) and Growth Rate (2015-2025)
Figure 27. Saudi Arabia Drugs for Metabolic Disorders Revenue (Value) and Growth Rate (2015-2025)
Figure 28. South Africa Drugs for Metabolic Disorders Revenue (Value) and Growth Rate (2015-2025)
Figure 29. Turkey Drugs for Metabolic Disorders Revenue (Value) and Growth Rate (2015-2025)
Figure 30. Global Drugs for Metabolic Disorders Sales Market Share by Manufacturer in 2019
Figure 31. Global Drugs for Metabolic Disorders Revenue Market Share by Manufacturer in 2019
Figure 32. Top 3 Drugs for Metabolic Disorders Manufacturer (Revenue) Market Share in 2019
Figure 33. Top 6 Drugs for Metabolic Disorders Manufacturer (Revenue) Market Share in 2019
Figure 34. Key Manufacturer Market Share Trend
Figure 35. Global Drugs for Metabolic Disorders Sales and Growth Rate (2015-2020) (K Units)
Figure 36. Global Drugs for Metabolic Disorders Revenue and Growth Rate (2015-2020) (USD Million)
Figure 37. Global Drugs for Metabolic Disorders Revenue Market Share by Regions (2015-2020)
Figure 38. Global Drugs for Metabolic Disorders Revenue Market Share by Regions in 2018
Figure 39. North America Drugs for Metabolic Disorders Sales and Growth Rate (2015-2020)
Figure 40. Europe Drugs for Metabolic Disorders Sales and Growth Rate (2015-2020)
Figure 41. Asia-Pacific Drugs for Metabolic Disorders Sales and Growth Rate (2015-2020)
Figure 42. South America Drugs for Metabolic Disorders Sales and Growth Rate (2015-2020)
Figure 43. Middle East & Africa Drugs for Metabolic Disorders Sales and Growth Rate (2015-2020)
Figure 44. North America Drugs for Metabolic Disorders Revenue and Growth Rate (2015-2020) (USD Million)
Figure 45. North America Drugs for Metabolic Disorders Sales Market Share by Countries (2015-2020)
Figure 46. North America Drugs for Metabolic Disorders Sales Market Share by Countries in 2018
Figure 47. North America Drugs for Metabolic Disorders Revenue Market Share by Countries (2015-2020) (USD Million)
Figure 48. North America Drugs for Metabolic Disorders Revenue Market Share by Countries in 2018
Figure 49. United States Drugs for Metabolic Disorders Sales and Growth Rate (2015-2020) (K Units)
Figure 50. Canada Drugs for Metabolic Disorders Sales and Growth Rate (2015-2020) (K Units)
Figure 51. Mexico Drugs for Metabolic Disorders Sales and Growth Rate (2015-2020) (K Units)
Figure 52. Europe Drugs for Metabolic Disorders Revenue and Growth Rate (2015-2020) (USD Million)
Figure 53. Europe Drugs for Metabolic Disorders Revenue Market Share by Countries (2015-2020)
Figure 54. Europe Drugs for Metabolic Disorders Revenue Market Share by Countries in 2019
Figure 55. Germany Drugs for Metabolic Disorders Sales and Growth Rate (2015-2020) (K Units)
Figure 56. UK Drugs for Metabolic Disorders Sales and Growth Rate (2015-2020) (K Units)
Figure 57. France Drugs for Metabolic Disorders Sales and Growth Rate (2015-2020) (K Units)
Figure 58. Russia Drugs for Metabolic Disorders Sales and Growth Rate (2015-2020) (K Units)
Figure 59. Italy Drugs for Metabolic Disorders Sales and Growth Rate (2015-2020) (K Units)
Figure 60. Asia-Pacific Drugs for Metabolic Disorders Revenue and Growth Rate (2015-2020) (USD Million)
Figure 61. Asia-Pacific Drugs for Metabolic Disorders Sales Market Share by Regions 2019
Figure 62. Asia-Pacific Drugs for Metabolic Disorders Revenue Market Share by Regions 2019
Figure 63. China Drugs for Metabolic Disorders Sales and Growth Rate (2015-2020) (K Units)
Figure 64. Japan Drugs for Metabolic Disorders Sales and Growth Rate (2015-2020) (K Units)
Figure 65. Korea Drugs for Metabolic Disorders Sales and Growth Rate (2015-2020) (K Units)
Figure 66. India Drugs for Metabolic Disorders Sales and Growth Rate (2015-2020) (K Units)
Figure 67. Southeast Asia Drugs for Metabolic Disorders Sales and Growth Rate (2015-2020) (K Units)
Figure 68. South America Drugs for Metabolic Disorders Revenue and Growth Rate (2015-2020) (USD Million)
Figure 69. South America Drugs for Metabolic Disorders Sales Market Share by Countries in 2019
Figure 70. South America Drugs for Metabolic Disorders Revenue Market Share by Countries in 2019
Figure 71. Brazil Drugs for Metabolic Disorders Sales and Growth Rate (2015-2020) (K Units)
Figure 72. Argentina Drugs for Metabolic Disorders Sales and Growth Rate (2015-2020) (K Units)
Figure 73. Middle East and Africa Drugs for Metabolic Disorders Revenue and Growth Rate (2015-2020) (USD Million)
Figure 74. Middle East and Africa Drugs for Metabolic Disorders Sales Market Share by Countries in 2019
Figure 75. Middle East and Africa Drugs for Metabolic Disorders Revenue Market Share by Countries (2015-2020)
Figure 76. Middle East and Africa Drugs for Metabolic Disorders Revenue Market Share by Countries in 2019
Figure 77. Saudi Arabia Drugs for Metabolic Disorders Sales and Growth Rate (2015-2020) (K Units)
Figure 78. Egypt Drugs for Metabolic Disorders Sales and Growth Rate (2015-2020) (K Units)
Figure 79. Turkey Drugs for Metabolic Disorders Sales and Growth Rate (2015-2020) (K Units)
Figure 80. South Africa Drugs for Metabolic Disorders Sales and Growth Rate (2015-2020) (K Units)
Figure 81. Global Drugs for Metabolic Disorders Sales and Growth Rate (2021-2025) (K Units)
Figure 82. Global Drugs for Metabolic Disorders Revenue and Growth Rate (2021-2025) (USD Million)
Figure 83. North America Sales Drugs for Metabolic Disorders Market Forecast (2021-2025) (K Units)
Figure 84. Europe Sales Drugs for Metabolic Disorders Market Forecast (2021-2025) (K Units)
Figure 85. Asia-Pacific Sales Drugs for Metabolic Disorders Market Forecast (2021-2025) (K Units)
Figure 86. South America Sales Drugs for Metabolic Disorders Market Forecast (2021-2025) (K Units)
Figure 87. Middle East & Africa Sales Drugs for Metabolic Disorders Market Forecast (2021-2025) (K Units)
Figure 88. Sales Channel: Direct Channel vs Indirect Channel
代謝障害治療の世界市場2020年：企業別、地域別、種類・用途別 Market Overview The global Metabolic Disorders Treatment market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Metabolic Disor…- アミノ酸代謝異常治療の世界市場（～2026年） Market Analysis and Insights: Global Amino Acid Metabolism Disorders Treatment Market The global Amino Acid Metabolism Disorders Treatment market size is projected to reach US$ 578.9 million by 2026, from US$ 547 million in 2020, at a CAGR of 5.3%% during 2021-2026. Global Amino Acid Metabolism Diso…
- グリコーゲン代謝性疾患治療薬の世界市場2020年：メーカー別、地域別、種類・用途別 Market Overview The global Drugs for Glycogen Metabolism Disease market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Drugs f…
- 脂質代謝疾患治療薬の世界市場2020年：メーカー別、地域別、種類・用途別 Market Overview The global Drugs for Lipid Metabolism Disease market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Drugs for …
- アミノ酸代謝異常症の世界市場2020年：企業別、地域別、種類・用途別 Market Overview The global Amino Acid Metabolism Disease market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Amino Acid Meta…